# Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML

> **NCT07643636** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dongguan People's Hospital** · enrollment: 46 (estimated)

## Conditions studied

- AML (Acute Myeloid Leukemia)

## Interventions

- **DRUG:** Chidamide (Chi)+VAH

## Key facts

- **NCT ID:** NCT07643636
- **Lead sponsor:** Dongguan People's Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643636, "Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*